Diagnosis and management of uterine serous carcinoma: current strategies and clinical challenges

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–17.
   PubMed Web of Science ®Google Scholar
• Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642.
   PubMed Web of Science ®Google Scholar
• Rauh-Hain JA, Diver E, Meyer LA, et al. Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: analysis of the National Cancer Database. Gynecol Oncol. 2015;139:77–83.
   PubMed Web of Science ®Google Scholar
• Lachance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2006;101:470–475.
   PubMed Web of Science ®Google Scholar
• Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol an Off J United States Can Acad Pathol Inc. 1997;10:963–968.
   PubMed Web of Science ®Google Scholar
• McCullough ML, Patel AV, Patel R, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Prev Biomarkers. 2008;17:73–79.
   PubMed Web of Science ®Google Scholar
• Bjørge T, Engeland A, Tretli S, et al. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer. 2007;120:378–383.
   PubMed Web of Science ®Google Scholar
• McGunigal M, Liu J, Kalir T, et al. Survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers: a National Cancer Database analysis. Int J Gynecol Cancer. 2017;27:85–92.
   PubMed Web of Science ®Google Scholar
• Maxwell GL, Tian C, Risinger J, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Interdiscip Int J Am Cancer Soc. 2006;107:2197–2205.
   Google Scholar
• Bregar AJ, Rauh-Hain JA, Spencer R, et al. Disparities in receipt of care for high-grade endometrial cancer: a National Cancer Data Base analysis. Gynecol Oncol. 2017;145:114–121.
   PubMed Web of Science ®Google Scholar
• Rauh-Hain JA, Buskwofie A, Clemmer J, et al. Racial disparities in treatment of high-grade endometrial cancer in the Medicare population. Obstet Gynecol. 2015;125(4):843–851..
   PubMed Web of Science ®Google Scholar
• Gehrig PA, Bae-Jump VL, Boggess JF, et al. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol. 2004;94:208–211.
   PubMed Web of Science ®Google Scholar
• Pierce SR, Stine JE, Gehrig PA, et al. Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. Gynecol Oncol. 2017;144:531–535.
   PubMed Web of Science ®Google Scholar
• Chan JK, Manuel MR, Cheung MK, et al. Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Gynecol. Oncol. 2006;102:508–512.
   Google Scholar
• Dewdney SB, Kizer NT, Andaya AA, et al. Uterine serous carcinoma: increased familial risk for lynch-associated malignancies. Cancer Prev Res. 2012;5:435–443.
   PubMed Web of Science ®Google Scholar
• Pennington KP, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer. 2013;119:332–338.
   PubMed Web of Science ®Google Scholar
• Kadan Y, Raviv O, Segev Y, et al. Impact of BRCA mutations on outcomes among patients with serous endometrial cancer. Int J Gynecol Obstet. 2018;142:91–96.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463–469.
   PubMed Web of Science ®Google Scholar
• Huang GS, Gebb JS, Einstein MH, et al. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol. 2007;196:243–e1.
   PubMed Web of Science ®Google Scholar
• Antonsen SL, Jensen LN, Loft A, et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer—a multicenter prospective comparative study. Gynecol Oncol. 2013;128:300–308.
   PubMed Web of Science ®Google Scholar
• Gee MS, Atri M, Bandos AI, et al. Identification of distant metastatic disease in uterine cervical and endometrial cancers with FDG PET/CT: analysis from the ACRIN 6671/GOG 0233 multicenter trial. Radiology. 2018;287:176–184.
   PubMed Web of Science ®Google Scholar
• Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, et al. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol. 2008;110:293–298.
   PubMed Web of Science ®Google Scholar
• Baek M-H, Lee S-W, Park J-Y, et al. Identification of a preoperative predictive factor for lymph node metastasis in uterine papillary serous carcinoma: long-term results from a single institution. Int J Gynecol Cancer. 2015;25:69–74.
   PubMed Web of Science ®Google Scholar
• Mattes MD, Lee JC, Metzger DJ, et al. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry. J Gynecol Oncol. 2015;26:19–24.
   PubMed Web of Science ®Google Scholar
• Todo Y, Kato H, Kaneuchi M, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375:1165–1172.
   PubMed Web of Science ®Google Scholar
• Alagkiozidis I, Weedon J, Grossman A, et al. Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous and endometrioid adenocarcinoma: a retrospective cohort study. Int J Surg. 2015;24:9–13.
   PubMed Web of Science ®Google Scholar
• Schiavone MB, Scelzo C, Straight C, et al. Survival of patients with serous uterine carcinoma undergoing sentinel lymph node mapping. Ann Surg Oncol. 2017;24:1965–1971.
   PubMedGoogle Scholar
• Smith AJB, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216:459–476.
   PubMed Web of Science ®Google Scholar
• Luz R, MacDonald N, Mould T. Omental biopsy for surgical staging of uterine serous carcinoma. Int J Gynecol Cancer. 2016;26:1448–1454.
   PubMed Web of Science ®Google Scholar
• Kaban A, Topuz S, Erdem B, et al. Is omentectomy necessary for non-endometrioid endometrial cancer. Gynecol Obstet Invest. 2018;83(5):482–486.
   PubMed Web of Science ®Google Scholar
• Giuntoli RL, Gerardi MA, Yemelyanova AV, et al. Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Cancer. 2012;22:273–279.
   PubMed Web of Science ®Google Scholar
• Thomas MB, Mariani A, Cliby WA, et al. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. 2007;107:190–193.
   PubMed Web of Science ®Google Scholar
• Alagkiozidis I, Grossman A, Tang NZ, et al. Survival impact of cytoreduction to microscopic disease for advanced stage cancer of the uterine corpus: A retrospective cohort study. Int J Surg. 2015;14:61–66.
   PubMed Web of Science ®Google Scholar
• Lee LJ, DeMaria R, Berkowitz R, et al. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. Gynecol Oncol. 2014;132:65–69.
   PubMed Web of Science ®Google Scholar
• Solmaz U, Mat E, Ekin A, et al. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas. Int J Surg. 2016;32:71–77.
   PubMed Web of Science ®Google Scholar
• Wilkinson-Ryan I, Frolova AI, Liu J, et al. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma. Int J Gynecol Cancer. 2015;25:63–68.
   PubMed Web of Science ®Google Scholar
• Fader AN, Java J, Tenney M, et al. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: an NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016;143:460–465.
   PubMed Web of Science ®Google Scholar
• Hanley KZ, Fadare O, Fisher KE, et al. Clinical significance of positive pelvic washings in uterine papillary serous carcinoma confined to an endometrial polyp. Int J Gynecol Pathol. 2016;35:249–255.
   PubMed Web of Science ®Google Scholar
• Zhong X, Wang J, Kaku T, et al. Prognostic Factors of Uterine Serous Carcinoma—A Multicenter Study. Int J Gynecol Cancer. 2018;28:1138–1144.
   PubMed Web of Science ®Google Scholar
• Tolcher MC, Swisher EM, Medeiros F, et al. Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early stage uterine serous carcinoma. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2015;34:57.
   PubMed Web of Science ®Google Scholar
• Kommoss F, Faruqi A, Gilks CB, et al. Uterine serous carcinomas frequently metastasize to the fallopian tube and can mimic serous tubal intraepithelial carcinoma. Am J Surg Pathol. 2017;41:161–170.
   PubMed Web of Science ®Google Scholar
• Black C, Feng A, Bittinger S, et al. Uterine papillary serous carcinoma: a single-institution review of 62 Cases. Int J Gynecol Cancer. 2016;26:133–140.
   PubMed Web of Science ®Google Scholar
• Qian Y, Pollom EL, Nwachukwu C, et al. Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma. Gynecol Oncol. 2017;147:24–29.
   PubMed Web of Science ®Google Scholar
• Winer I, Ahmed QF, Mert I, et al. Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence? Int J Gynecol Pathol. 2015;34:47–56.
   PubMed Web of Science ®Google Scholar
• Fader AN, Starks D, Gehrig PA, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2009;115:244–248.
   PubMed Web of Science ®Google Scholar
• Kuhn E, Wu R-C, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst. 2012;104:1503–1513.
   PubMed Web of Science ®Google Scholar
• Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci. 2013;110:2916–2921.
   PubMed Web of Science ®Google Scholar
• Levine DA, Network CGAR. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67.
   PubMed Web of Science ®Google Scholar
• Le Gallo M, O’Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 2012;44:1310.
   PubMed Web of Science ®Google Scholar
• Kuhn E, Bahadirli-Talbott A, Shih I-M. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod Pathol. 2014;27:1014.
   PubMed Web of Science ®Google Scholar
• Mahdi H, Xiu J, Reddy SK, et al. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma. J Surg Oncol. 2015;112:188–194.
   PubMed Web of Science ®Google Scholar
• Jones NL, Xiu J, Reddy SK, et al. Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma. Gynecol Oncol. 2015;138:620–626.
   PubMed Web of Science ®Google Scholar
• Mhawech‐Fauceglia P, Yan L, Liu S, et al. ER+/PR+/TFF 3+/IMP 3− immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases. Histopathology. 2013;62:976–985.
   PubMed Web of Science ®Google Scholar
• Buza N, English DP, Santin AD, et al. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol. 2013;26:1605–1612.
   PubMed Web of Science ®Google Scholar
• Jones NL, Xiu J, Chatterjee‐Paer S, et al. Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. Int J Cancer. 2017;140:1396–1404.
   PubMed Web of Science ®Google Scholar
• Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016;387:1094–1108.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Van Stedum S, et al. Amplification of c‐erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104:1391–1397.
   PubMed Web of Science ®Google Scholar
• Togami S, Sasajima Y, Oi T, et al. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER 2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci. 2012;103:926–932.
   PubMed Web of Science ®Google Scholar
• Divine LM, Nguyen MR, Meller E, et al. AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. Oncotarget. 2016;7:77291.
   PubMedGoogle Scholar
• Beirne JP, Quinn JE, Maxwell P, et al. BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma. Int J Gynecol Cancer. 2013;23:113–118.
   PubMed Web of Science ®Google Scholar
• Mahdi H, Han X, Moulton L, et al. Trends in survival of patients with uterine serous carcinoma from 1988 to 2011: a population-based study. Int J Gynecol Cancer. 2017;27:1155–1164.
   PubMedGoogle Scholar
• Fader AN, Drake RD, O’Malley DM, et al. Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115:2119–2127.
   PubMed Web of Science ®Google Scholar
• Fader AN, Nagel C, Axtell AE, et al. Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol. 2009;112:558–562.
   PubMed Web of Science ®Google Scholar
• Boothe D, Williams N, Odei B, et al. The addition of adjuvant chemotherapy to radiation in early-stage high-risk endometrial cancer: survival outcomes and patterns of care. Int J Gynecol Cancer. 2017;27:912–922.
   PubMed Web of Science ®Google Scholar
• Dietrich III CS, Modesitt SC, DePriest PD, et al. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2005;99:557–563.
   PubMed Web of Science ®Google Scholar
• Kelly MG, O’Malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol. 2005;98:353–359.
   PubMed Web of Science ®Google Scholar
• Shinde A, Li R, Amini A, et al. Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology. Gynecol Oncol. 2018;151:82–90.
   PubMed Web of Science ®Google Scholar
• Cham S, Huang Y, Tergas AI, et al. Utility of radiation therapy for early-stage uterine papillary serous carcinoma. Gynecol Oncol. 2017;145:269–276.
   PubMed Web of Science ®Google Scholar
• de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:295–309.
   PubMed Web of Science ®Google Scholar
• Randall ME, Filiaci V, McMeekin DS, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early-stage endometrial cancer. J Clin Oncol. 2019;37:1810.
   PubMed Web of Science ®Google Scholar
• Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112:543–552.
   PubMed Web of Science ®Google Scholar
• Miller D, Filiaci V, Fleming G, et al. Randomized phase Ill noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. ACADEMIC PRESS INC ELSEVIER SCIENCE 525 B ST, STE 1900, SAN DIEGO, CA 92101 …. 2012;771. DOI:10.1016/j.ygyno.2012.03.034.
   Google Scholar
• Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380:2317–2326.
   PubMed Web of Science ®Google Scholar
• Lin JF, Muñiz K, Sukumvanich P, et al. Survival advantage associated with multimodal therapy in women with node‐positive (stage‐IIIC) uterine papillary serous carcinoma: a National Cancer Database study. BJOG An Int J Obstet Gynaecol. 2016;123:1846–1852.
   PubMed Web of Science ®Google Scholar
• Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. 2018;
   Google Scholar
• Tortorella L, Langstraat CL, Weaver AL, et al. Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy. Gynecol Oncol. 2018;149:291–296.
   PubMed Web of Science ®Google Scholar
• Mahdi H, Rizzo A, Rose PG. Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy. Int J Gynecol Cancer. 2015;25:467–473.
   PubMed Web of Science ®Google Scholar
• Ebeid K, Meng X, Thiel KW, et al. Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol. 2018;13:72.
   PubMed Web of Science ®Google Scholar
• Palisoul ML, Quinn JM, Schepers E, et al. Inhibition of the receptor tyrosine kinase AXL restores paclitaxel chemosensitivity in uterine serous cancer. Mol Cancer Ther. 2017;16:2881–2891.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Gokden M, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;8:1271–1279.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–1791.
   PubMed Web of Science ®Google Scholar
• English DP, Bellone S, Schwab CL, et al. T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Med. 2014;3:1256–1265.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Buza N, et al. Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1). Gynecol Oncol reports. 2017;19:10–12.
   PubMed Web of Science ®Google Scholar
• Black J, Menderes G, Bellone S, et al. SYD985, a novel duocarmycin-based HER2-targeting antibody–drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2/Neu expression. Mol Cancer Ther. 2016;15:1900–1909.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–119.
   PubMed Web of Science ®Google Scholar
• El-Sahwi K, Bellone S, Cocco E, et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer. 2010;102:134–143.
   PubMed Web of Science ®Google Scholar
• Growdon WB, Groeneweg J, Byron V, et al. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant. Gynecol Oncol. 2015;137:160–166.
   PubMed Web of Science ®Google Scholar
• Todeschini P, Cocco E, Bellone S, et al. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. Br J Cancer. 2011;105:1176.
   PubMed Web of Science ®Google Scholar
• Black JD, Lopez S, Cocco E, et al. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. Br J Cancer. 2015;113:1020.
   PubMed Web of Science ®Google Scholar
• Schwab CL, Bellone S, English DP, et al. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Br J Cancer. 2014;111:1750.
   PubMed Web of Science ®Google Scholar
• Schwab CL, English DP, Roque DM, et al. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol. 2014;135:142–148.
   PubMed Web of Science ®Google Scholar
• Lopez S, Schwab CL, Cocco E, et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol. 2014;135:312–317.
   PubMed Web of Science ®Google Scholar
• Lopez S, Cocco E, Black J, et al. Dual HER2/PIK3CA targeting overcomes single-agent acquired resistance in HER2-amplified uterine serous carcinoma cell lines in vitro and in vivo. Mol Cancer Ther. 2015;14:2519–2526.
   PubMed Web of Science ®Google Scholar
• Myers AP, Konstantinopoulos PA, Barry WT, et al. Phase II, 2 stage, 2 arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer. Int J Cancer. 2019;142:413-422.
   PubMed Web of Science ®Google Scholar
• Cocco E, Lopez S, Black J, et al. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. Br J Cancer. 2016;115:303.
   PubMed Web of Science ®Google Scholar
• English DP, Roque DM, Carrara L, et al. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol Oncol. 2013;131:753–758.
   PubMed Web of Science ®Google Scholar
• Hernandez SF, Chisholm S, Borger D, et al. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation. Gynecol Oncol. 2016;141:570–579.
   PubMed Web of Science ®Google Scholar
• Bellone S, Roque D, Cocco E, et al. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br J Cancer. 2012;106:1543.
   PubMed Web of Science ®Google Scholar
• Bellone S, Black J, English DP, et al. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. Am J Obstet Gynecol. 2016;214:99–e1.
   PubMed Web of Science ®Google Scholar
• Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:711–718.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Filiaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018;150:274–281.
   PubMed Web of Science ®Google Scholar
• Mallen AR, Filiaci VL, Levine DA, et al. Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers. Gynecol Oncol. 2018;149:29–30.
   Web of Science ®Google Scholar
• Haines K, Huang GS. Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A. Cancer Res. 2019;79:4009–4010.
   PubMed Web of Science ®Google Scholar
• Taylor SE, O’Connor CM, Wang Z, et al. The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis. Cancer Res. 2019;79(16):4242–4257. canres-0218..
   Web of Science ®Google Scholar
• Bonazzoli E, Predolini F, Cocco E, et al. Inhibition of BET bromodomain proteins with GS-5829 and GS-626510 in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Clin Cancer Res. 2018;24:4845–4853.
   PubMed Web of Science ®Google Scholar
• Roque DM, Bellone S, English DP, et al. Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer. 2013;119:2582–2592.
   PubMed Web of Science ®Google Scholar